GSK/$GSK
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
68,629
ISIN
US37733W2044
Website
GSK Metrics
BasicAdvanced
$77B
36.71
$1.05
0.27
$1.53
4.39%
Price and volume
Market cap
$77B
Beta
0.27
52-week high
$44.67
52-week low
$31.72
Average daily volume
4.8M
Dividend rate
$1.53
Financial strength
Current ratio
0.868
Quick ratio
0.575
Long term debt to equity
120.653
Total debt to equity
134.993
Dividend payout ratio (TTM)
78.91%
Interest coverage (TTM)
10.32%
Profitability
EBITDA (TTM)
11,892.413
Gross margin (TTM)
71.92%
Net profit margin (TTM)
10.00%
Operating margin (TTM)
19.83%
Effective tax rate (TTM)
13.90%
Revenue per employee (TTM)
$632,130
Management effectiveness
Return on assets (TTM)
6.55%
Return on equity (TTM)
27.10%
Valuation
Price to earnings (TTM)
36.71
Price to revenue (TTM)
3.618
Price to book
4.01
Price to tangible book (TTM)
-6.29
Price to free cash flow (TTM)
28.135
Free cash flow yield (TTM)
3.55%
Free cash flow per share (TTM)
136.49%
Dividend yield (TTM)
3.99%
Forward dividend yield
4.39%
Growth
Revenue change (TTM)
2.57%
Earnings per share change (TTM)
-30.07%
3-year revenue growth (CAGR)
5.66%
10-year revenue growth (CAGR)
3.20%
3-year earnings per share growth (CAGR)
-15.47%
10-year earnings per share growth (CAGR)
-11.61%
3-year dividend per share growth (CAGR)
-12.88%
10-year dividend per share growth (CAGR)
-4.67%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
Bulls say / Bears say
GSK announced a $2.5 billion share buyback and raised its long-term sales target to nearly $50 billion, driven by strong performance in HIV and cancer drug sales. (reuters.com)
Berenberg reaffirmed its Buy rating on GSK stock, maintaining the price target at £18.20, citing confidence in the company's strategic progress in HIV treatments. (investing.com)
GSK reported a 35% year-on-year increase in consolidated profit for its Indian subsidiary, driven by strong demand for respiratory drugs and the antibiotic Augmentin. (reuters.com)
UBS downgraded GSK's stock rating from Buy to Neutral, adjusting the price target to £15.80 from £20.40, citing revised expectations for the company's products and financial performance. (investing.com)
Hedge fund Citadel took a short position in GSK, amounting to 305 million pounds, indicating a bet that the company's stock will decline. (reuters.com)
GSK reached agreements to settle U.S. state court Zantac product liability cases for up to $2.2 billion, which could impact the company's financial position. (financecharts.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
GSK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul10
GSK
Dividend·Payment
$0.429088Per share
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $77B as of July 01, 2025.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 36.71 as of July 01, 2025.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is $1.53157 and the yield is 4.39%. GSK has a payout ratio of 78.91% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment is scheduled for July 10, 2025.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.